U.S., Aug. 28 -- ClinicalTrials.gov registry received information related to the study (NCT07143773) titled 'SGLT2i Safety and Efficacy on Kidney Allograft Function in Non-diabetic Kidney Transplant Recipients' on July 30.
Brief Summary: This clinical trial investigates whether 18 months of daily SGLT2i (10 mg Forxiga) preserves kidney function and evaluates safety, based on eGFR changes and adverse event occurrence in non-diabetic kidney transplant recipients.
The main questions it aims to answer are:
* Does SGLT2i versus placebo, as an add-on to standard care, preserve kidney transplant function in non-diabetic recipients?
* Is SGLT2i treatment safe for non-diabetic transplant recipients when evaluating adverse events?
* Does SGLT2i ...